Work

Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations

Year: 2010

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1097/jto.0b013e3181dd1386

Authors: Wee-Lee Yeo, Gregory J. Riely, Beow Y. Yeap, Michelle W. Lau, Jeremy L. Warner, Kelly Bodio, Mark S. Huberman, Mark G. Kris, Daniel G. Tenen, William Pao, Susumu Kobayashi, Daniel B. Costa

Institutions: Beth Israel Deaconess Medical Center, Harvard University, National University of Singapore, Cancer Science Institute of Singapore, Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, Vanderbilt University, Vanderbilt-Ingram Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Institutes of Health, National Cancer Institute

Awards: G1827975024, Role of EGFR mutations and new therapeutics in lung cancer, G3679683216, Overcoming acquired resistance to EGFR inhibitors in lung cancer, G458608165, G72612885

OpenAlex ID: W2018708014

FWCI: 6.141

Cites: 39

Cited by: 83

Related to: 10